Information Journal Paper
APA:
Copy. (2019). Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, singlearm, dose-escalation trial. LANCET INFECTIOUS DISEASES, 19(9), 1013-1022. SID. https://sid.ir/paper/747813/en
Vancouver:
Copy. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, singlearm, dose-escalation trial. LANCET INFECTIOUS DISEASES[Internet]. 2019;19(9):1013-1022. Available from: https://sid.ir/paper/747813/en
IEEE:
Copy, “Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, singlearm, dose-escalation trial,” LANCET INFECTIOUS DISEASES, vol. 19, no. 9, pp. 1013–1022, 2019, [Online]. Available: https://sid.ir/paper/747813/en